Cargando…

PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions

Poly(ADP-ribose) polymerase (PARP) inhibitors cause targeted tumour cell death in homologous recombination (HR)-deficient cancers, including BRCA-mutated tumours, by exploiting synthetic lethality. PARP inhibitors are being evaluated in late-stage clinical trials of ovarian cancer (OC). Recently, ol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Konecny, G E, Kristeleit, R S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5104889/ https://www.ncbi.nlm.nih.gov/pubmed/27736844 http://dx.doi.org/10.1038/bjc.2016.311

Ejemplares similares

Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer
por: Nicoletto, Maria Ornella, et al.
Publicado: (2023)

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
por: Annunziata, Christina M, et al.
Publicado: (2010)

Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors
por: O’Sullivan, Ciara C., et al.
Publicado: (2014)

PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival
por: Shao, Fengping, et al.
Publicado: (2021)

The role of PARP inhibitors in BRCA mutated pancreatic cancer
por: Chi, Jeffrey, et al.
Publicado: (2021)

Natural phytochemicals prevent side effects in BRCA-mutated ovarian cancer and PARP inhibitor treatment
por: Wang, Chuanlin, et al.
Publicado: (2022)

Combining PARP and CDK4/6 inhibitors in MYC driven ovarian cancer
por: Konecny, Gottfried E.
Publicado: (2019)

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
por: Colombo, Ilaria, et al.
Publicado: (2018)

Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer
por: Jiang, Xuan, et al.
Publicado: (2019)

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
por: Hodgson, Darren R., et al.
Publicado: (2018)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
por: Yang, Shicheng, et al.
Publicado: (2023)

Prevalence of BRCA1 Mutations in Familial and Sporadic Greek Ovarian Cancer Cases
por: Stavropoulou, Alexandra V., et al.
Publicado: (2013)

Roles of the PARP Inhibitor in BRCA1 and BRCA2 Pathogenic Mutated Metastatic Prostate Cancer: Direct Functions and Modification of the Tumor Microenvironment
por: Inoue, Takahiro, et al.
Publicado: (2023)

Current and Future Directions for PARP Inhibition
por: Grudem, Megan, et al.
Publicado: (2020)

BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
por: Petrelli, Annalisa, et al.
Publicado: (2023)

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance
por: Nesic, Ksenija, et al.
Publicado: (2023)

Correction: Prevalence of BRCA1 Mutations in Familial and Sporadic Greek Ovarian Cancer Cases
por: Stavropoulou, Alexandra V., et al.
Publicado: (2013)

VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status
por: Bizzaro, Francesca, et al.
Publicado: (2021)

Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors
por: Faraoni, Isabella, et al.
Publicado: (2018)

Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic Approaches
por: Dilmac, Sayra, et al.
Publicado: (2023)

PARP inhibitors in ovarian cancer
por: Cibula, David, et al.
Publicado: (2015)

Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options
por: Garg, Vikas, et al.
Publicado: (2023)

Mutation Analysis of BRCA1 and BRCA2 in Italian Hereditary and Sporadic Forms of Breast and Ovarian Cancers: Tumor Genotype-Phenotype Correlation in Breast Cancer BRCA-Mutation Carriers
por: Cipollini, G., et al.
Publicado: (1999)

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting
por: Dziadkowiec, Karolina N., et al.
Publicado: (2017)

PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer
por: Dickson, Kristie-Ann, et al.
Publicado: (2021)

Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer
por: Vendrell, Julie A., et al.
Publicado: (2023)

Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer
por: Rafii, Saeed, et al.
Publicado: (2017)

The dynamic landscape of BRCA1 reversion mutations from indel to SNV in a patient with ovarian cancer treated with PARP-inhibitors and immunotherapy
por: Jacob, Saya L., et al.
Publicado: (2020)

Corrected Allele Frequency of BRCA1/2 Mutations Is an Independent Prognostic Factor for Treatment Response to PARP-Inhibitors in Ovarian Cancer Patients
por: Grech, Christina T., et al.
Publicado: (2022)

PARP Inhibitor Insensitivity to BRCA1/2 Monoallelic Mutations in Microsatellite Instability-High Cancers
por: Sokol, Ethan S., et al.
Publicado: (2022)

Invasive bilateral breast cancer and high grade serous ovarian cancer with BRCA1-germline mutation and brainstem metastasis under PARP inhibitors
por: Zahari, Mihaela Mărioara, et al.
Publicado: (2021)

MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer
por: Bustos, Matias A., et al.
Publicado: (2023)

BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers
por: Vos, Shoko, et al.
Publicado: (2017)

Clinical features and outcomes of germline mutation BRCA1-linked versus sporadic ovarian cancer patients
por: Synowiec, Agnieszka, et al.
Publicado: (2016)

BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different
por: Burgess, Melissa, et al.
Publicado: (2014)

BRCA1 as a Therapeutic Target in Sporadic Epithelial Ovarian Cancer
por: Clark-Knowles, Katherine V., et al.
Publicado: (2010)

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
por: Kondrashova, Olga, et al.
Publicado: (2018)

Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer
por: Hollis, Robert L, et al.
Publicado: (2017)

PARP Inhibitors in Breast and Ovarian Cancer
por: Wang, Samuel S. Y., et al.
Publicado: (2023)

Tumor BRCA Test for Patients with Epithelial Ovarian Cancer: The Role of Molecular Pathology in the Era of PARP Inhibitor Therapy
por: Fumagalli, Caterina, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2smbi914cubj8obfd7kisiqbq8